Suppr超能文献

吸入性过敏原过敏患者用重组变应原进行成分分辨诊断。

Component resolved diagnosis by recombinant allergens in patients with allergies to inhalants.

机构信息

Department of Translational Medical Sciences, University of Naples "Federico II", Naples, Italy.

Institute of Experimental Endocrinology and Oncology "G. Salvatore" (National Research Council), Naples, Italy.

出版信息

J Biol Regul Homeost Agents. 2020;34(5):1729-1737. doi: 10.23812/20-297-A.

Abstract

Molecular characterization of IgE reactivity of specific individual components of allergenic extracts is now possible due to the technology of recombinant allergens derived from studies of molecular biology of allergic pathology. The identification of the immunoreactivity to single allergenic components in allergic subjects allows to specifically define her/his allergic profile and obtain the so-termed Component Resolved Diagnosis (CRD). Molecular allergens can be classified into those that induce the respiratory allergic reactivity and those that identify the food-related allergic pathology. It is also essential to identify those molecular allergens whose immunoreactivity is able to connect the two clinical conditions: respiratory symptoms and food allergy symptoms. The present study was conducted on 50 patients with a clinical history of hypersensitivity to pollen and/or allergy and positivity to Skin Prick Test. The sera were analyzed in our laboratories and the panel of recombinant allergens was applied in the case of positivity of the specific IgE. Of the 50 patients enrolled, 31 were selected as positive to 4 main pan-allergen Bet v1, Par j2, Art v1 and Phl p1; among these, 14 subjects showed one allergen-specific IgE towards natural extracts of tested foods even in absence of clinical history. CRD allows for an increased accuracy in allergy diagnosis and prognosis and plays an important role in: a) resolving genuine vs cross-reactive sensitization in poly-sensitized patients, b) assessing, in selected cases, the risk of severe, systemic vs mild, local reactions in food allergy, and c) identifying patients and triggering allergens for specific immunotherapy (ITS). In light of our results, we believe that the transition from a diagnostic based on the use of allergenic extracts to another one based on the use of single allergenic molecules that is able to define the specific allergenic profile of each patient, seems to be able to revolutionize the allergy diagnosis.

摘要

由于过敏病理分子生物学研究中的重组过敏原技术,现在可以对过敏原提取物中特定个体成分的 IgE 反应性进行分子特征分析。在过敏患者中鉴定对单一过敏原成分的免疫反应性,可以特异性地确定其过敏谱,并获得所谓的“成分分辨诊断”(CRD)。分子过敏原可分为引起呼吸道过敏反应的过敏原和鉴定与食物相关的过敏病理的过敏原。识别那些能够将两种临床情况(呼吸道症状和食物过敏症状)联系起来的免疫反应性的分子过敏原也是至关重要的。本研究对 50 例具有花粉过敏和/或过敏史和皮肤点刺试验阳性的患者进行了研究。在我们的实验室中分析了这些血清,并在特异性 IgE 阳性的情况下应用了重组过敏原面板。在纳入的 50 例患者中,有 31 例对 4 种主要 pan-allergen(Bet v1、Par j2、Art v1 和 Phl p1)呈阳性;其中,14 例患者即使没有临床病史,也对测试食物的天然提取物表现出一种过敏原特异性 IgE。CRD 可提高过敏诊断和预后的准确性,并在以下方面发挥重要作用:a)在多敏患者中区分真正的和交叉反应性致敏;b)在特定情况下评估食物过敏中严重的全身性 vs 轻度的局部反应风险;c)确定患者和引发过敏的特定免疫疗法(ITS)的触发过敏原。基于我们的结果,我们认为从基于使用过敏原提取物的诊断向基于能够定义每个患者特定过敏原谱的单一过敏原分子的诊断转变,似乎能够彻底改变过敏诊断。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验